Search Result

Results for "

hemophilia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Factor VIIa (2) Factor VIII (2) Factor Xa (5) Liposome (1) Small Interfering RNA (siRNA) (2)
By Research Areas:	Cardiovascular Disease (1) Metabolic Disease (2)
Oligonucleotides:	Aptamers (2) Cationic Lipids (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132587A

Fitusiran sodium ALN-AT3SC sodium; SAR439774 sodium	Factor Xa	Others
Fitusiran sodium, an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran sodium increases thrombin generation and has the potential for the research of the hemophilia .

HY-150224

GalNAc unconjugated/naked Fitusiran sodium	Small Interfering RNA (siRNA) Factor Xa	Others
GalNAc unconjugated/naked Fitusiran (sodium), an small interfering RNA without GalNAc conjugation, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia .

HY-P99769

Omfiloctocog alfa SCT-800	Factor VIII	Metabolic Disease
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .

HY-P9940

Emicizumab	Factor VIII	Cardiovascular Disease
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .

HY-145405

C12-200 5+ Cited Publications	Liposome	Others
C12-200 is a type of ionizable cationic lipid and helper lipid commonly used for mRNA delivery. In the hemophilia B mouse model, mRNA encoding human erythropoietin (EPO) and coagulation factor IX (FIX) can be successfully delivered and expressed using C12-200. C12-200 is utilized in research related to hemophilia B .

HY-153480A

ARC19499 sodium BAX499 sodium	Factor Xa Factor VIIa	Others
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-E70393

Human Factor VIIa	Factor VIIa	Others
Human Factor VIIa is a vitamin K-dependent serine protease that is involved in the blood coagulation process. Human Factor VIIa activates Factor X, which causes the conversion of prothrombin to thrombin and the conversion of fibrinogen to fibrin, leading to the formation of blood clots. Human Factor VIIa exhibits the potential to ameliorate Hemophilia .

HY-132587

Fitusiran ALN-AT3SC; SAR439774	Small Interfering RNA (siRNA) Factor Xa	Others
Fitusiran (ALN-AT3SC), an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia .

HY-153480

ARC19499 BAX499	Factor Xa	Others
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

Cat. No.	Product Name

HY-L171

Anti-Hematopathy Compound Library	2,930 compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 2,930 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Anti-Hematopathy Compound Library

2,930 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 2,930 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Cat. No.	Product Name	Type

HY-145405

C12-200 5+ Cited Publications	Drug Delivery
C12-200 is a type of ionizable cationic lipid and helper lipid commonly used for mRNA delivery. In the hemophilia B mouse model, mRNA encoding human erythropoietin (EPO) and coagulation factor IX (FIX) can be successfully delivered and expressed using C12-200. C12-200 is utilized in research related to hemophilia B .

Cat. No.	Product Name	Target	Research Area

HY-P5496

AAV2 Epitope	Peptides	Others
AAV2 Epitope is a biological active peptide. (This peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells.)

Cat. No.	Product Name	Target	Research Area

HY-P99769

Omfiloctocog alfa SCT-800	Factor VIII	Metabolic Disease
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .

HY-P9940

Emicizumab	Factor VIII	Cardiovascular Disease
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .

HY-P99725

Marstacimab PF-06741086	Inhibitory Antibodies	Metabolic Disease
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia .

HY-P99283

Concizumab NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody	Inhibitory Antibodies	Others
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .

Cat. No.	Product Name		Classification

HY-132587A

Fitusiran sodium ALN-AT3SC sodium; SAR439774 sodium		siRNAs
Fitusiran sodium, an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran sodium increases thrombin generation and has the potential for the research of the hemophilia .

HY-150224

GalNAc unconjugated/naked Fitusiran sodium		siRNAs
GalNAc unconjugated/naked Fitusiran (sodium), an small interfering RNA without GalNAc conjugation, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia .

HY-145405

C12-200 5+ Cited Publications		Cationic Lipids
C12-200 is a type of ionizable cationic lipid and helper lipid commonly used for mRNA delivery. In the hemophilia B mouse model, mRNA encoding human erythropoietin (EPO) and coagulation factor IX (FIX) can be successfully delivered and expressed using C12-200. C12-200 is utilized in research related to hemophilia B .

HY-153480A

ARC19499 sodium BAX499 sodium		Aptamers
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-132587

Fitusiran ALN-AT3SC; SAR439774		siRNAs
Fitusiran (ALN-AT3SC), an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia .

HY-153480

ARC19499 BAX499		Aptamers
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.